UNSPSC 51313108: Buclizine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C28H33ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C94V6X681, chemically known as piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-.alpha.-phenylbenzyl)-, dihydrochloride but generally known as buclizine, which bears US NIH Compound Identifier 6729. Buclizine most often comes in base, dihydrochloride, and hydrochloride forms.

UNSPSC 51313108 Buclizine, a Commodity code, nominally addresses antihistamine pharmaceuticals, but the recent state and local activity under this code does not align with buclizine procurement — instead, Seminole County, Florida has posted solicitations for naloxone and drug deactivation systems. State and local governments use this code classification to buy emergency medical supplies and harm-reduction equipment for public health and community safety programs, though the actual buclizine product line shows limited recent procurement activity in the state and local market. Issuing bodies under related pharmaceutical and medical-supply codes tend to be county health departments, municipal public health agencies, and emergency management offices that support opioid response and community health initiatives.

Seminole County, Florida accounts for the recent visible activity under this code tier. The county issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The procurement carries an initial two-year term with one-year renewal option, includes E-Verify and drug-free workplace certification requirements, and is potentially funded through FEMA with corresponding federal compliance obligations. Vendors must provide unit costs, absorb all shipping and delivery expenses, and maintain workers' compensation, commercial general liability, and professional liability insurance. The code shows limited recent state and local solicitation volume; buyers evaluating pursuit should verify whether the specific product line (buclizine versus naloxone or harm-reduction systems) aligns with their capability and service footprint before committing resources to pipeline development under this classification.